Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 3, 1998, Pages 819-823

  Prigeon, Ronald L ^a,b   Kahn, Steven E ^a   Porte Jr , Daniel ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Rehabilitation Care Services S 117   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETES CONTROL; DIABETES MELLITUS; FEMALE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CHROMANS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031767928     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.3.819     Document Type: Article

References (36)

1. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte Jr D. 1984 Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest. 74:1318-1328.
2. Porte Jr D. 1991 Banting lecture. 1990 Beta-cells in type II diabetes mellitus. Diabetes. 40:166-180.
3. Duckworth WC, Kitabchi AE, Heinemann M. 1972 Direct measurement of plasma proinsulin in normal and diabetic subjects. Am J Med. 53:418-427.
4. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte Jr D. 1987 Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and experimental insulin resistance. Diabetologia. 30:698-702.
5. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY. 1995 Relationship of proinsulin and insulin with noninsulin dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity - clinical research center study. J Clin Endocrinol Metab. 80:1399-1406.
6. Saad MF, Kahn SE, Nelson RG, et al. 1990 Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 70:1247-1253.
7. Iwamoto Y, Kuzuya T, Matsuda A, et al. 1991 Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 14:1083-1086.
8. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. 1992 Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:193-203.
9. Khoursheed M, Miles PDG, Gao K-M, Lee M-K, Moossa AR, Olefsky JM. 1995 Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. Metabolism. 44:1489-1494.
10. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM. 1994 Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 331:1188-1193.
11. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. 1996 The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:3299-3306.
12. Berkowitz K, Peters R, Kjos SL, et al. 1996 Effect of troglitaznne on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM. Diabetes. 45:1572-1579.
13. Prigeon RL, Jacobson RK, Porte Jr D, Kahn SE. 1996 Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 81:3295-3298.
14. Welch S, Gebhart SSP, Bergman RN, Phillips LS. 1990 Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab. 71:1508-1518.
15. Prigeon RL, Roder ME, Porte Jr D, Kahn SE. 1996 The effect of insulin dose on the measurement of insulin sensitivity by the minimal model technique: evidence for saturable insulin transport in humans. J Clin Invest. 97:501-507.
16. Morgan DR, Lazarow A. 1963 Immunoassay of insulin: two antibody system: plasma insulin levels of normal, subdiabetic, and diabetic rats. Diabetes. 12:115-126.
17. Ward WK, Paquette TL, Frank BH, Porte Jr D. 1986 A sensitive radioimmunoassay for human proinsulin with sequential use of antisera to C-peptide and insulin. Clin Chem. 32:728-733.
18. Bergman RN, Ider YZ, Bowden CR, Cobelli C. 1979 Quantitative estimation of insulin sensitivity. Am J Physiol 236:E667-E677.
19. Kahn SE, Klaff LJ, Schwartz MW, et al. 1990 Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose. J Clin Endocrinol Metab. 71:994-1002.
20. Gorden P, Hendricks CM, Roth J. 1974 Circulating proinsulin-like component in man: increased proportion in hypoinsulinemic states. Diabetologia. 10:469-474.
21. Røder ME, Kahn SE, Porte Jr D. 1995 Disproportionate hyperproinsulinemia reflects the degree of B-cell dysfunction in NIDDM [Abstract]. Diabetes. 44(Suppl 1):156A.
22. Kahn SE, Beard JC, Schwartz MW, et al. 1989 Increased B-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 38:562-568.
23. Kahn SE, McCulloch DK, Schwartz MW, Palmer JP, Porte Jr D. 1992 Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus. J Clin Endocrinol Metab. 74:192-197.
24. Mako ME, Starr JI, Rubenstein AH. 1977 Circulating proinsulin in patients with maturity onset diabetes. Am J Med. 63:865-869.
25. Gadot M, Ariav Y, Cerasi E, Kaiser N, Gross DJ. 1995 Hyperproinsulinemia in the diabetic Psammomys obesus is a result of increased secretory demand on the β-cell. Endocrinology. 136:4218-4223.
26. Alarcon C, Leahy JL, Schuppin GT, Rhodes CJ. 1995 Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus. J Clin Invest. 95:1032-1039.
27. Nauck MA, Siegel EG, Creutzfeldt W. 1991 Prolonged maximal stimulation of insulin secretion in healthy subjects does not provoke preferential release of proinsulin. Pancreas. 6:645-652.
28. Hartling SG, Roder ME, Dinesen B, Binder C. 1996 Proinsulin, C-peptide, and insulin in normal subjects during an 8-h hyperglycemic clamp. Eur J Endocrinol. 134:197-200.
29. Inoue Y, Tanigawa K, Nakamura S, et al. 1995 Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats. Diabetes Res Clin Pract. 27:19-26.
30. Masuda K, Okamoto Y, Tsuura Y, et al. 1995 Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia. 38:24-30.
31. Fujiwara T, Wada M, Fukuda K, et al. 1991 Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism. 40:1213-1218.
32. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. 1988 Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1549-1558.
33. Kumar S, Boulton AJM, Beck-Nielsen H, et al. 1996 Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 39:701-709.
34. Ciaraldi TP, Huber-Knudsen K, Hickman M, Olefsky JM. 1995 Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism. 44:976-982.
35. Kahn SE, Bradbury VL, Beard JC, et al. 1990 Effect of exercise on insulin action, glucose tolerance and insulin secretion in aging. Am J Physiol 258:E937-E943.
36. Kahn SE, Prigeon RL, McCulloch DK, et al. 1994 The contribution of insulin-dependent and insulin-independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes. 43:587-592.